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Abstract
Background: Cardiovascular disease (CVD) is the leading cause of death in Russia. Hypertension and hyperlipidemia
are important risk factors for CVD that are modifiable by pharmacological treatment and life-style changes. We
aimed to characterize the extent of the problem in a typical Russian city by examining the prevalence, treatment
and control rates of hypertension and hyperlipidemia and investigating whether the specific pharmacological
regimes used were comparable with guidelines from a country with much lower CVD rates.
Methods: The Izhevsk Family Study II included a cross-sectional survey of a population sample of 1068 men, aged
25–60 years conducted in Izhevsk, Russia (2008–2009). Blood pressure and total cholesterol were measured and
self-reported medication use was recorded by a clinician. We compared drug treatments with the Russian and
Canadian treatment guidelines for hypertension and hyperlipidemia.
Results: The prevalence of hypertension was 61 % (age-standardised prevalence 51 %), with 66 % of those with
hypertension aware of their diagnosis and 50 % of those aware taking treatment. 17 % of those taking treatment
achieved blood pressure control. The majority (59 %) of those taking treatment were not doing so regularly.
Prevalence of hyperlipidemia was 45 % (age-standardised prevalence 40 %), however less than 2 % of those with
hyperlipidemia were taking any treatment. Types of lipid-lowering and anti-hypertensive medications prescribed
were broadly in line with Russian and Canadian guidelines.
Conclusion: The prevalence of hypertension and hyperlipidemia is high in Izhevsk while the proportion of those
treated and attaining treatment targets is very low. Prescribed medications were concurrent with those in Canada,
but adherence is a major issue.
Keywords: Hypertension, Hyperlipidemia, Russia, Prevalence, Treatment, Antihypertensive agents,
Anticholesterolemic agents
Background
Cardiovascular disease (CVD) is currently the leading
cause of death worldwide [1]. The situation is striking in
Russia, where levels of CVD mortality are among the
highest in the world particularly for men [2–4].
Over the past five decades, Western countries have
enjoyed a decline in CVD morbidity and mortality [5, 6].
This trend can be attributed to improved medical treat-
ment and to population-level changes in exposure to
CVD risk factors [5–8]. Canada is an example of a country
where cardiovascular health promotion has become a pri-
ority on the national agenda. Guidelines for physicians on
the diagnosis and treatment of hypertension and hyperlip-
idemia have been implemented [9, 10]. Education pro-
grams on CVD prevention are in place, and resources for
management of risk factors are accessible to patients and
the public [9, 10].
The situation is different in Russia. The longest period
of decline in CVD mortality for many decades only started
in 2005/6 and is still ongoing. Moreover, concerted efforts
to develop a modern national strategy and infrastructure
to address CVD morbidity and mortality have only been
prioritized over the past 10–12 years. In 2006, President
Vladimir Putin launched the National Priority Project
Health to improve primary care and disease prevention,
and to facilitate accessibility to tertiary care and maternal
and child health services [11]. In 2008, the priorities were
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expanded to include a reduction in CVD mortality [11]. In
2009, the Pharmaceutical 2020 concept was introduced to
improve CVD detection and treatment by implementing
patient registers, with the desired aim of introducing a
more comprehensive drug insurance plan to cover pre-
scription medications [11, 12]. In 2011, outpatient
pharmaceutical coverage was expanded to include certain
CVD drugs.
Hypertension and hyperlipidemia are key areas to inves-
tigate since these are modifiable risk factors for CVD
which can be controlled with lifestyle change and pharma-
cological intervention [1]. Russia has published guidelines
for the investigation and treatment of hypertension and
hyperlipidemia that broadly follow the European guide-
lines [13]. These are mainly consistent with Canadian
guidelines however very little is known about the specific
types of medications prescribed and the frequency of use
among individuals to whom they have been prescribed.
We investigated the prevalence and pharmacological
treatment practices of hypertension and hyperlipidemia
among working-age men in the city of Izhevsk, Russia,
focusing on specific drugs prescribed, in order to assess
how these compare to those recommended elsewhere.
The fieldwork for this study occurred in 2008–9, after
the start of the CVD mortality decline and the introduc-
tion of a range of national strategies. Although improve-
ments may have occurred more recently, this study is
one of only a very small number to look in detail at the
profile of pharmacological treatments employed in
Russia at any point in the past decade.
Methods
Study design
The data analysed were from the Izhevsk Family Study II
(IFS-2), a cross-sectional study of 1,531 working-age
men (25–60 years) conducted in Izhevsk, Russia. Izhevsk
is a medium-sized industrial city situated in the Western
Ural region. Participants were originally recruited as
controls for a case-control study of the association
between hazardous drinking and mortality (2003–05)
derived from a 2002 list of city residents frequency
matched by age to cases [14]. IFS-2 involved following
up the control men in 2008–9.
IFS-2 had two parts. First, participants were inter-
viewed face-to-face by trained interviewers at their own
home, where data were collected on socio-demographic
factors and health behaviours including questions on
smoking status. Men were then invited to a health check
performed by a physician at a clinic 2–3 weeks after the
interview. There were 1,068 men who took part in this
second stage. The distribution of socio-demographic and
health behaviour variables were very similar between the
men who attended the health check and those who did
not. Only the data from the men who attended the
health check were used in our analyses.
The health check involved a complete medical history
collected using a doctor-administered questionnaire and
a standard medical examination. Seated systolic blood
pressure (SBP) and diastolic blood pressure (DBP) were
measured three times using Omron (705 IT) electronic
sphygmomanometers. Participants were asked if they
were aware of whether their blood pressure was higher
in one arm and if so this arm was used for measure-
ment. The mean of the second and third readings were
used to determine hypertension prevalence and control.
Three measures of waist and hip circumference were
taken, height measurements used the SECA Leicester
Portable Height Measure, and weight measurements
were taken using Tanita HS-1632 electronic weighing
scales. Means of these values were used to calculate
mean body mass index and mean waist to hip ratio.
A non-fasting blood sample was also collected during
the health check on the same day as blood pressure
measurement. Samples were transported to a local
laboratory where they were spun and aliquoted within
12 h of venipuncture. Aliquots were stored at −80 °C
and transported to the Lytech laboratory in Moscow,
where lipid assays were performed. These included high-
density lipoprotein cholesterol (HDL-C), triglycerides
and total cholesterol (TC). Low-density lipoprotein
cholesterol (LDL-C) level was estimated using the
Friedwald equation.
The names of any medications taken, their prescribed
dose, and frequency of use were self-reported by partici-
pants and recorded as text. This information was trans-
lated and coded by an English-speaking Russian
cardiologist into their corresponding generic (English)
names and each medication was classified according to
primary function (e.g. anti-hypertensive or lipid-lowering).
We compared findings from Izhevsk with Canadian
guidelines, which are similar to those from Western
Europe. Since the implementation of the Canadian
Hypertension Education Program (CHEP) in 1999,
there have been marked increases in the diagnosis
and treatment of hypertension in Canada [15].
Hypertension measures
Standard definitions of hypertension used for compara-
tive purposes in this paper were as given in the 2012
Canadian Hypertension Education Program [10]. Hyper-
tension prevalence was defined as SBP ≥140 mmHg
and/or DBP ≥90 mmHg and/or self-reported use of pre-
scribed drugs for BP control at the time of the health
check. The data used to determine awareness and treat-
ment of hypertension were obtained from participants’
responses to the doctor-administered questionnaire.
Hypertension awareness was defined as any self-reported
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prior diagnosis of hypertension by a doctor or nurse,
amongst those defined as hypertensive. The following
questions were used: ‘Have you ever had your blood
pressure measured by a doctor or a nurse?’ and ‘Have
you ever been told by a doctor or nurse that you had
high blood pressure?’ Hypertension treated was defined
as self-reported use of a medication prescribed by a doc-
tor for the management of high BP daily or intermit-
tently, amongst those defined as hypertension aware.
The following questions were used: ‘Has a doctor pre-
scribed drugs to control your blood pressure?’ and (if
yes) ‘Do you take these drugs?’ Options for participants
were ‘Daily’ or ‘Only sometimes when I feel unwell
(coded as intermittently)’ and ‘Never’. Hypertension con-
trolled was defined as mean SBP <140 mmHg and/or
DBP <90 mmHg, amongst those who reported having
been prescribed anti-hypertensives.
Hyperlipidemia measures
Definitions of hyperlipidemia used for comparative
purposes in this paper were adapted from the 2009
Canadian Cardiovascular Society Guidelines for the
Diagnosis and Treatment of Dyslipidemia [9]. Hyper-
lipidemia prevalence was defined as LDL-C
≥3.5 mmol/L and/or TC/HDL-C ≥5 and/or use of
prescribed lipid-lowering medications at the time of
the health check. The self-reported prescribed lipid-
lowering medications recorded during the health
check were used to determine treatment of hyperlip-
idemia amongst those defined as hyperlipidemic. No
questions were included related to self-reported
awareness of hyperlipidemia. Hyperlipidemia con-
trolled was defined as LDL-C <3.5 mmol/L and TC/
HDL-C <5 amongst those defined as hyperlipidemia
treated.
Analyses
The prescribed anti-hypertensive medications used by
participants were compared with the treatment guide-
lines in the 2012 Canadian Hypertension Education
Program [10]. Anti-hypertensive pharmacotherapy ac-
cording to these guidelines is summarized in Fig. 1. Two
analyses were done. In the first, all anti-hypertensive
medications recorded were analyzed by frequency of
prescription and whether or not they were currently pre-
scribed in Canada. The second analysis investigated
first-line pharmacotherapy judged by examining pre-
scriptions among men only taking a single anti-
hypertensive drug (including single pill combination
drugs). Since no health records were available it was not
possible to distinguish separately those who may have
changed drugs treatments but this still allows us to dis-
tinguish preferential prescription of monotherapies.
The prescribed lipid-lowering medications used by
participants were compared against the 2009 Canadian
Cardiovascular Society Guidelines for the Diagnosis and
Treatment of Dyslipidemia [9]. According to the guide-
lines, a statin should be initial pharmacotherapy for
adults with hyperlipidemia without other compelling
medical conditions. If statin therapy is not tolerated,
Fig. 1 Anti-hypertensive Pharmacotherapy Treatment Guidelines in 2012 Canadian Hypertension Education Programme
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LDL-C may be lowered using niacin, bile acid resins,
cholesterol absorption blockers, and fibrates. Due to very
low levels of hyperlipidemia treatment among study par-
ticipants, only an assessment of whether or not the
lipid-lowering medications were concurrent with those
prescribed in Canada was performed.
Statistical analyses were performed using STATA 12
[16]. Cross-tabulations were performed to provide es-
timates of prevalence, awareness, treatment, and con-
trol of hypertension and hyperlipidemia. Prevalence of
hypertension and hyperlipidemia were directly stan-
dardised by age using the 1976 European Standard
Population so results could be compared with the
ESSE-RF study carried out in nine regions of Russia
between 2012 and 2013 [17].
Results
A total of 1068 men attended the health check. The
mean age was 48.1 years. The age distribution was
skewed left, with more men in older age categories. The
majority of men did not use medications of any kind
(71 %). Most (97 %) reported ever having had their BP
measured by a doctor or nurse. There were 669 men
(62.6 %) who were current smokers. Mean body mass
index was 26.3 (SD 4.4) and mean waist to hip ratio was
0.93 (SD 0.07). The prevalence of abdominal obesity
defined as mean waist to hip ratio >0.9 was 64.8 %. Dis-
tribution of the sample by hypertension stage according
to measured blood pressure (not accounting for use of
anti-hypertensive medications) was 334 (31.5 %) of the
sample had stage 1 hypertension (SBP 140–159 mm Hg
Fig. 2 Number of men included and excluded in hypertension prevalence, aware, treated and controlled categories
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or DBP 90–99 mm Hg) and 281 (26.5 %) of the
sample had stage 2 hypertension (SBP ≥160 mm Hg
or DBP ≥100 mm Hg).
Hypertension
The flowchart in Fig. 2 shows for hypertension how the
men included in the study were classified according to
information obtained about awareness, diagnosis, treat-
ment and results at the health check. Of the 1068 men
who underwent the health check, BP was successfully
measured in 1061 men. The prevalence of hypertension
was 61 % (651/1061). The age standardized prevalence
of hypertension was 51 %.
Table 1 shows the distribution by age of hypertension
prevalence, awareness, treatment, and control amongst
those taking treatment for hypertension. Prevalence,
awareness and treatment all increased with age, however
control showed the opposite effect.
Among those taking prescribed anti-hypertensive
medication, less than half (41 %) (85/205) were taking
treatment every day (Table 2).
Types of anti-hypertensive medication
There were 128 men taking one or more prescribed
anti-hypertensive medications according to the drugs
named in the list of medications.
Table 3 shows the types of anti-hypertensive drugs
used, the number of times each drug was reported, for
all men and for men taking one drug only (monother-
apy), and whether or not the drug is currently prescribed
in Canada. Drugs have been arranged by class in the
order of frequency by which they were prescribed in
Izhevsk. ACE Inhibitors (ACE-I) were the most common
drugs reported (43 % of prescriptions). The use of com-
bination therapy was very low (11 %). A local medication
(Reserpine) was recorded twice (<2 %). With the excep-
tion of the local medication, all the prescribed anti-
hypertensive drugs taken by the men are also currently
prescribed in Canada.
Among men the 90 men on monotherapy (taking one
anti-hypertensive drug only) half were taking an ACE-I.
With the exception of one man taking an α-blocker, all
men were taking a drug considered compatible with
first-line anti-hypertensive therapy in Canada.
Hyperlipidemia
The flowchart in Fig. 3 shows inclusion criteria for
hyperlipidaemia analyses. Of the 1068 men who under-
went the health check, blood lipid measurements were
available for 980 men (92 %). The prevalence of hyper-
lipidemia was 45 % (443/980). The age standardized
prevalence was 40 %.
Amongst those classified as hyperlipidemia prevalent,
less than 2 % (eight men) were taking lipid-lowering medi-
cations. Of those taking medications, 38 % (3/8) men
achieved blood lipid control. Seven of these men were tak-
ing Simvastatin and one man was taking a lipid lowering
drug which was not classified by name. Additionally there
was one man who had no lipid measurement available
who was taking Atorvastatin. Both Simvastatin and Ator-
vastatin are currently prescribed in Canada for first-line
medical treatment of hyperlipidemia.
Discussion
In this population-based study of working-age men in
Izhevsk 2008–9, Russia, we found low rates of control of
hypertension and that among those men prescribed anti-
hypertensives very few took them regularly. Even more
striking was the finding that very few people with hyper-
lipidemia (<2 %) were taking lipid-lowering medication.
Nonetheless, the specific types of anti-hypertensive and
lipid-lowering medications reported as being taken by
participants were broadly consistent with those recom-
mended in clinical guidelines in both Russia and a high
income country (Canada) with much lower CVD mortal-
ity. Thus the high rate of CVD mortality observed in this
Russian population is unlikely to be explained by the use
of out-dated or ineffective pharmaceuticals. However the
findings from this study indicate that the extent of
pharmaceutical prescriptions and levels of adherence to
treatment could be important factors contributing to
high mortality from CVD in Russia.
Table 1 Hypertension prevalence and percentage of those with hypertension who are aware, treated, and controlled by age
Prevalencea Awarenessb Treatedc Controlledd
Age (years) Total N % Total N % Total N % Total N %
25–39 189 74 39.15 70 39 55.71 37 13 35.14 13 5 38.46
40–49 328 187 57.01 178 109 61.24 109 43 39.45 43 9 20.93
50–60 544 390 71.69 386 269 69.69 265 149 56.23 149 20 13.42
25–60 1061 651 61.36 634 417 65.77 411 205 49.88 205 34 16.59
aHypertension prevalence: Mean of the second and third SBP readings ≥140 mmHg and/or DBP ≥90 mmHg and/or self-reported use of prescribed drugs for
BP control
bHypertension awareness: Any self-reported, prior diagnosis of hypertension by a doctor or nurse, amongst those defined as hypertension prevalent
cHypertension treated: Self-reported use of a medication prescribed by a doctor for the management of high BP daily or intermittently, amongst those defined as
hypertension aware excluding those who reported they did not know if they had been prescribed hypertension medication (n = 6)
dHypertension controlled: Mean of the second and third SBP readings <140 mmHg and DBP <90 mmHg, amongst those defined as hypertension treated
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The prevalence of hypertension in our study was 61 %
(age-standardised prevalence 51 %). In the most recent
study ESSE-RF performed in nine regions of the Russian
Federation in 2012–2013 age-standardised prevalence of
hypertension in men aged 25–64 years was 48.2 %, very
similar to our findings [17]. However this is high com-
pared with data from the Federal hypertension monitor-
ing program (2003–2010) which showed the age-
standardised prevalence of hypertension as 38 % in men
although as the age range for this population is much
wider than in our study (15–75 years) these results are
not directly comparable with Izhevsk [18]. A study by
Mozheyko et al. investigating control levels amongst
hypertensive patients in the Yaroslavl region of Russia
found at baseline, the level of blood pressure control
amongst those taking anti-hypertensive treatment was
16.8 %. Control rates improved to 23.0 % at 1-year
follow-up [19]. In the recent ESSE-RF study levels of
control among men receiving treatment was higher
(41.4 %) although overall levels of blood pressure control
in all men with hypertension was 14.4 % [17]. In contrast
in the nationally representative Canadian Health Mea-
sures Study (2007–9) prevalence of hypertension among
adults aged 20–79 years old in Canada was estimated at
19.7 % while levels of treatment and control were not-
ably higher compared with Russian studies with 79 % of
those with hypertension taking regular treatment and
64.6 % of those with hypertension both treated and con-
trolled [20]. Although prevalence estimates are not dir-
ectly comparable since data from the Canadian Health
Measures Survey were not age-standardised the differ-
ence in prevalence is so large it is unlikely to be com-
pletely explained by differences in age structure of the
study populations.
Effective blood pressure control depends on patient
adherence since target blood pressure can only be
achieved and maintained with regular, daily therapy.
However in our study approximately 60 % of men pre-
scribed medication for hypertension did not take it on a
daily basis. Our findings are consistent with a recent
population-based study by Roberts et al. on hypertension
treatment in countries of the former Soviet Union,
which found that approximately three quarters of people
taking anti-hypertensive medications were not taking
them every day [21]. Studies of adherence in primary
care settings shows low adherence even in patients at a
specialised clinic with complicated hypertension [22]. All
these studies suggest irregular use of hypertension medi-
cation is a major issue. Use of combination therapy may
help with treatment adherence by simplifying treatment
regimes when more than one drug is prescribed. The
use of combination therapies has increased over the last
decade in Canada, the US and Western Europe [23–25]
however in our study, in keeping with other recent stud-
ies in Russia [19, 26], the use of combination therapies
was relatively low.
To our knowledge, this is the first population study to
investigate in detail type of prescribed medications used
for treatment of hypertension in Russia. Our findings
are consistent with studies from clinical settings that
prescribed medical treatments for hypertension are
modern and in keeping with medical guidelines from
both Russia and Canada [22, 27, 28]. We believe this is
the first study to investigate detailed treatment of hyper-
lipidemia in any setting in Russia. Age standardised
prevalence of hyperlipidemia in our study from 2009
(40 %) was slightly lower than from the more recent
ESSE-RF study from 2012 to 2013 (47.8 %) [29, 30] and
the Canadian Health Measures Survey (45 % not age-
standardised). This is high compared to the WHO
MONICA study which surveyed participants in Novosibirsk
and Moscow between 1992 and 1995 (age standardized
range in men 8–16 %) although the threshold used for
hyperlipidemia was higher (total cholesterol ≥6.5 mmol/L
or use of lipid lowering medication) [31]. However there
were substantial differences between Izhevsk and the
Canadian Health Measures Study with regards the levels of
pharmacological treatment for hyperlipidemia with less than
2 % of men with hyperlipidemia taking lipid lowering medi-
cations in Izhevsk compared to 24 % of people with hyper-
lipidemia in Canada [32]. Nonetheless, the medications
taken were the same as those prescribed in Canada. It is
worth noting that even though more people were on treat-
ment for hyperlipidemia in the Canadian Health Measures
Table 2 Frequency of taking hypertension treatment prescribed by a doctor by age
Age (years) Takes treatment dailya Takes treatment intermittentlyb Treated totalc
N % N % N %
25–39 4 31 9 69 13 100
40–49 15 35 28 65 43 100
50–60 66 44 83 56 149 100
25–60 85 41 120 59 205 100
aMen who report taking hypertension treatment prescribed by a doctor every day, amongst those defined as hypertension treated
bMen who report taking hypertension treatment prescribed by a doctor intermittently (less than once daily), amongst those defined as hypertension treated
cHypertension treated: Self-reported use of a prescription medication for the management of high BP daily or intermittently, amongst those defined as
hypertension aware
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Survey, the overall levels of treatment and of control in
Canada were still low (19 % controlled) suggesting improve-
ments could be made in both countries [32]. Levels of treat-
ment in Russia for hyperlipidemia in the MONICA study
(1992–95) showed a great deal of variation ranging by
centre with 6–25 % of men (20–79 % women) with hyper-
lipidemia prescribed medications in Moscow and 0–48 % in
Novosibirsk (0–39 % in women) [31]. Findings from our
study are also supported by those from a recent large multi-
centre study of 18,273 patients visiting primary care facilities
in Russia which found that half of those with hypercholes-
teremia were not prescribed treatment [33]. One possible
explanation for the low treatment levels found in Izhevsk
may stem from differences in preventative practices. A
study by Pardell et al. [34] noted that routine blood choles-
terol assessments were performed much less frequently by
Russian primary care doctors in comparison to those in
Western European countries. The reasons for this are not
well understood. Cost may be a factor in explaining this
since the routine measurement of blood lipids is an
Table 3 Prescription frequency of anti-hypertensive medications by type for all men (N = 173 prescriptions) and for men taking
monotherapy (N = 90 prescriptions)
All anti-hypertensive drugs (100 % of prescriptions) Total Monotherapy Prescribed in Canada
N N
173 90
Thiazide Diuretics (3.5 % of total prescriptions) Indapamide 5 3 Yes
Hydrochlorothiazide 1 – Yes
Total 6 3
ACE-Inhibitors (42.8 % of total prescriptions) Enalapril 58 36 Yes
Lisinopril 7 5 Yes
Perindopril 6 4 Yes
Captopril 1 – Yes
Fosinopril 1 – Yes
Ramipril 1 – Yes
Total 74 45
ARBs (0.6 % of total prescriptions) Losartan 1 – Yes
Total 1 0
Calcium-Channel Blockers (11.6 % of total
prescriptions)
Nifedipine 8 2 Yes
Verapamil 7 1 Yes
Amilodipine 5 1 Yes
Total 20 4
β-Blockers (28.9 % of total prescriptions) Metoprolol 32 13 Yes
Bisoprolol 15 8 Yes
Propranolol 2 – Yes
Carvediol 1 – Yes
Total 50 21
Combination therapies (11.1 % of total prescriptions)
ACE-Inhibitor & Diuretic (6.8 % of total
prescriptions)
Perindopril & Indapamide 8 7 Yes
Enalapril & Indapamide 1 1 No. Drugs prescribed separately.
Enalapril &
Hydrochlorothiazide
1 – Yes
Beta-Blocker & Diuretic (6.2 % of total
prescriptions)
Atenolol & Chlortalidone 9 8 Yes
Total 19 16
α-Blockers (0.6 % of total prescriptions) Clonidine 1 1 Yes
Total 1 1
Local Medications (1.2 % of total
prescriptions)
Reserpine (Rauwolfia
alkaloid)
2 – No. Drug not prescribed due to serious adverse
side effects.
Total 2 0
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expensive clinical practice [34]. However insufficient statin
treatment has been found even among patients on clinical
registers under physician care with very high cardiovascular
risk profiles and severe hypercholesterolemia [35, 36]. Al-
though cost may be a factor in the low levels of statins pre-
scribed, a wide range of cheap generic statins are currently
available in Russia. We consider lack of knowledge and un-
derstanding of the importance of statin therapy by physi-
cians and thus subsequently by patients likely to be a key
factor in this. Clinical guidelines in Russia are very similar
to Europe as they are translated and adapted from the
guidelines of the European Society of Cardiology. The state
of knowledge concerning the efficacy of statins in the
Russian medical profession is underlined by a recent study
of physician health in Russia which found that physicians
themselves do not take statins even if they are at very high
risk of cardiovascular disease (only 13 % of physicians who
needed statin treatment actually took it) [37]. If physicians
themselves do not think it is necessary to take statins
themselves this decreases the chance of systematic prescrip-
tion of statins to patients. Current physician attitudes to sta-
tins may be related to the fact that active promotion of
statins by big pharmaceutical companies did not occur dur-
ing the Soviet Union when drugs were still on patent. The
reasons for the particularly low levels of treatment of hyper-
lipidemia and what can be done to improve this is a key
area for further investigation.
It is important to note that the data we used and our
analyses have several limitations.
Firstly our sample size was relatively small, particularly
affecting the hyperlipidemia investigations with only 8
men taking lipid-lowering medications. Although we
could not perform extensive investigations of lipid-
lowering medications, the small number is an important
finding in itself, as it reflects the extremely low levels of
treatment. Our hyperlipidemia analyses were also limited
by less extensive data collection compared to the hyper-
tension data. No questions were asked in the study
Fig. 3 Number of men included and excluded in hyperlipidemia prevalence, treated and controlled categories
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about awareness of hyperlipidemia, and whether or not
participants had ever had their blood lipids measured.
Such data would have been valuable to better assess
primary care practices.
In addition our study did not collect information on
the use of complementary and alternative medicine
(CAM). CAM and other folk medical practices have
been well-documented in Russia, and laws regulating
these practices in Russia are limited [38]. It is therefore
possible that the patients with hypertension and hyper-
lipidemia in our sample were using non-prescribed ther-
apies, which may in part explain the low levels of
conventional pharmacological treatment reported. Medi-
cations used were also self-reported by participants and
therefore subject to measurement error. Blood pressure
(measured three times) was only taken on one occasion
in a clinic setting where it may be raised artificially due
to medical environment and therefore the prevalence of
hypertension may be over-estimated compared to clinic-
ally diagnosed hypertension that would require confirm-
ation from a subsequent office blood pressure or use of
a 24 h ambulatory device. In line with standard practice
to minimize measurement error due to “white coat
hypertension” only the second and third measurements
were used in our analyses. Finally, there may have been
some measurement error in the levels of hyperlipidemia
since the study samples were non-fasting whereas the
guidelines for identification were for fasting samples.
This could have led to an overestimate of the true preva-
lence of hyperlipidemia. However the levels of treatment
for hyperlipidemia were so low that the gap between
prevalence and treatment is very unlikely to be explained
by fasting status.
In terms of generalizability to the whole of Russia the
study is very limited as it was conducted only in one city
among working-age men and are therefore not applic-
able to women or the elderly. However, it could be
regarded as a strength that it was conducted in a provin-
cial city, and not one of the large metropolitan cities
where standards of care might be expected to be the
highest, but atypical of Russia as a whole.
It is also important to note our study was conducted
in 2008–9. Since then, a national screening program for
chronic diseases “Dispanserization” has been introduced
in Russia. The situation therefore may have changed.
More recent studies are needed investigating the impact
of this program of CVD prevention and management.
Findings from this study are important in understanding
any changes in management which may have arisen
from this initiative.
Conclusions
Among a population-based sample of working-age men
in Izhevsk the prevalence of both hypertension and
hyperlipidemia was high and the levels of control of
both conditions were extremely low. Among those with
hypertension patient adherence to treatment was a par-
ticular issue whereas for hyperlipidemia hardly any men
received treatment at all. Given both hypertension and
hyperlipidemia are both important modifiable risk fac-
tors for CVD, which is the leading cause of death in
Russia, this is a crucial public health issue.
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